Cargando…

The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats

OBJECTIVE(S): Diabetic neuropathy (DN) is a common complication of diabetes that leads to allodynia, impaired nerve conduction, and progressive sensory loss. The aim of this study was to observe the effect of a high-affinity cannabinoid receptors agonist, WIN 55,212-2, on thermal hyperalgesia, nerve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jahanabadi, Samane, Hadian, Mohamad Reza, Shamsaee, Javad, Tavangar, Seyed Mohammad, Abdollahi, Alireza, Dehpour, Ahmadreza, Mehr, Shahram Ejtemaei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887712/ https://www.ncbi.nlm.nih.gov/pubmed/27279983

Ejemplares similares

Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain
por: Marchalant, Y, et al.
Publicado: (2009)

Role of Nitric Oxide in the Antipruritic Effect of WIN 55,212-2, a Cannabinoid Agonist
por: Gercek, Oyku Zeynep, et al.
Publicado: (2020)

Cannabinoid WIN55,212-2 reprograms monocytes and macrophages to inhibit LPS-induced inflammation
por: Pérez-Diego, Mario, et al.
Publicado: (2023)

Microinjection of WIN55,212-2 as A Cannabinoid Agonist into The Basolateral Amygdala Induces Sensitization to Morphine in Rats
por: Molaei, Marzieh, et al.
Publicado: (2014)

Consequences of Adolescent Exposure to the Cannabinoid Receptor Agonist WIN55,212-2 on Working Memory in Female Rats
por: Kirschmann, Erin K., et al.
Publicado: (2017)

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells
por: Morell, C, et al.
Publicado: (2016)

Gestational exposure to the cannabinoid WIN 55,212-2 and its effect on the innate intestinal immune response
por: Hernández-Cervantes, Rosalía, et al.
Publicado: (2019)

Minimum Alveolar Concentration of Isoflurane in Rats Chronically Treated with the Synthetic Cannabinoid WIN 55,212-2
por: Chavez-Monteagudo, Julio Raul, et al.
Publicado: (2022)

A male mouse model of WIN 55,212–2 self-administration to study cannabinoid addiction
por: Cajiao-Manrique, María del Mar, et al.
Publicado: (2023)

Dose-dependent effect of cannabinoid WIN-55,212-2 on myelin repair following a demyelinating insult
por: Tomas-Roig, J., et al.
Publicado: (2020)

WIN 55,212-2, Agonist of Cannabinoid Receptors, Prevents Amyloid β(1-42) Effects on Astrocytes in Primary Culture
por: Aguirre-Rueda, Diana, et al.
Publicado: (2015)

Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2
por: Scholl, Antje, et al.
Publicado: (2016)

Cannabinoid WIN 55,212-2 Inhibits Human Glioma Cell Growth by Triggering ROS-Mediated Signal Pathways
por: Wang, Kun, et al.
Publicado: (2021)

Behavioral and Neurochemical Changes in Mesostriatal Dopaminergic Regions of the Rat after Chronic Administration of the Cannabinoid Receptor Agonist WIN55,212-2
por: Fanarioti, Eleni, et al.
Publicado: (2015)

WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells
por: Wasik, A M, et al.
Publicado: (2011)

WIN55,212-2, a Dual Modulator of Cannabinoid Receptors and G Protein-Coupled Inward Rectifier Potassium Channels
por: An, Dongchen, et al.
Publicado: (2021)

Retracted: Cannabinoid WIN 55,212-2 Inhibits Human Glioma Cell Growth by Triggering ROS-Mediated Signal Pathways
por: International, BioMed Research
Publicado: (2023)

A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats
por: Goonawardena, Anushka V., et al.
Publicado: (2011)

Cannabinoid WIN-55,212-2 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1
por: KONG, YING, et al.
Publicado: (2016)

The effect of cannabinoid receptor agonist WIN 55,212–2 on anxiety‐like behavior and locomotion in a genetic model of absence seizures in the elevated plus‐maze
por: Cassar, Daniel, et al.
Publicado: (2022)

Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat
por: Vera, Gema, et al.
Publicado: (2023)

PKCε Regulates Behavioral Sensitivity, Binding and Tolerance to the CB1 Receptor Agonist WIN55,212-2
por: Wallace, Melisa J., et al.
Publicado: (2009)

CB(1) receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2
por: Németh, Beáta, et al.
Publicado: (2008)

Cannabinoid WIN-55,212-2 mesylate inhibits tumor necrosis factor-α-induced expression of nitric oxide synthase in dorsal root ganglion neurons
por: Tan, Rong, et al.
Publicado: (2018)

Involvement of the CB(2) cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma
por: Khan, Mohammed I., et al.
Publicado: (2018)

Memantine Prevents the WIN 55,212-2 Evoked Cross-Priming of Ethanol-Induced Conditioned Place Preference (CPP)
por: Marszalek-Grabska, Marta, et al.
Publicado: (2021)

Alterations in Rat Accumbens Dopamine, Endocannabinoids and GABA Content During WIN55,212-2 Treatment: The Role of Ghrelin
por: Charalambous, Chrysostomos, et al.
Publicado: (2020)

Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2
por: Radziszewska, Elżbieta, et al.
Publicado: (2013)

Sex Differences in the Behavioral and Synaptic Consequences of a Single in vivo Exposure to the Synthetic Cannabimimetic WIN55,212-2 at Puberty and Adulthood
por: Borsoi, Milene, et al.
Publicado: (2019)

THC exposure during adolescence increases impulsivity-like behavior in adulthood in a WIN 55,212-2 self-administration mouse model
por: Cajiao-Manrique, María del Mar, et al.
Publicado: (2023)

Enhanced self-administration of the CB(1) receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms
por: Amchova, Petra, et al.
Publicado: (2014)

Effects of WIN 55,212-2 (a non-selective cannabinoid CB(1) and CB(2) receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model
por: Florek-Luszczki, Magdalena, et al.
Publicado: (2014)

WIN55,212-2-Induced Expression of Mir-29b1 Favours the Suppression of Osteosarcoma Cell Migration in a SPARC-Independent Manner
por: Notaro, Antonietta, et al.
Publicado: (2019)

WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2
por: Aragão, Luiz Guilherme H. S., et al.
Publicado: (2021)

The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB(2), TRPV1, TRPA1 and yet unidentified receptor targets
por: Lowin, Torsten, et al.
Publicado: (2016)

WIN55,212-2 Attenuates Cognitive Impairments in AlCl(3) + d-Galactose-Induced Alzheimer’s Disease Rats by Enhancing Neurogenesis and Reversing Oxidative Stress
por: Mahdi, Onesimus, et al.
Publicado: (2021)

Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
por: Feng, Ya-Jing, et al.
Publicado: (2016)

Cannabinoid Receptor Agonist WIN55, 212-2 Attenuates Injury in the Hippocampus of Rats after Deep Hypothermic Circulatory Arrest
por: Yu, Ming-Huan, et al.
Publicado: (2023)

Cannabinoid receptor agonist WIN55212-2 reduces unpredictable mild stress-induced depressive behavior of rats
por: Zhong, Chao-Chao, et al.
Publicado: (2021)

Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice
por: Aguilar, María A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c8sra0b546btkao5lhbkhiqekv